SynthesisFrontiers in oncology2024

Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials.

Chaithra N et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.